La cadena de opciones muestra datos clave de las opciones de acciones de Corsair Gaming a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Corsair Gaming..

Corsair Gaming (NASDAQ:CRSR) Bolsa, Cadena de Opciones

Corsair Gaming

Corsair Gaming Inc is engaged in the business of providing high-performance gear for gamers and content creators. The product portfolio includes Cases, Keyboards, Mice, Headsets, Power Supplies, Gaming Computers, Gaming Chairs, Mousepads, and other related products. The company operates in two segments namely, Gamer and Creator peripherals, which is the key revenue-generating segment; and Gaming Components and Systems. Geographically, the group derives revenue from the Americas, Europe and the Middle East, and the Asia Pacific.

Corsair Gaming Inc

DA Davidson analyst Michael Baker maintains A-Mark Precious Metals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMRK#NASDAQ">AMRK</a>) with a Buy and lowers the price target from $52 to $43.

News

Price Target

Analyst Ratings

AMRK

DA Davidson Maintains Buy on A-Mark Precious Metals, Lowers Price Target to $43

The Federal Reserve lowered interest rates by 0.25 percentage points on Thursday, as widely anticipated by the market, bringing the federal funds rate to a target range of 4.5% to 4.75%, the <a href="https://www.benzinga.com/topic/interest-rates">lowest since February 2023. </a>
With this decision, the Fed slowed the pace of rate cuts compared to September, when policymakers opted for a more substantial 0.5% cut to initiate the easing cycle.
The Fed's November policy statement continued to highlight that the economy has expanded at a &#8220;solid pace,&#8221; job growth &#8220;has generally eased&#8221; and inflation &#8220;has made further progress&#8221; toward the 2% target, although it remains &#8220;somewhat elevated.&#8221;
The Personal Consumption Expenditure (PCE) inflation rate eased to 2.1% year-over-year in September 2024, marking its smallest increase since February 2021. The Fed&#8217;s preferred inflation measure, the core PCE price index, which excludes food and energy, remained steady at 2.7%.
Yet the November statement surprisingly omitted a line from September that stated: &#8220;The Committee has gained greater confidence that inflation is moving sustainably toward 2 percent and judges that the risks to achieving its employment and inflation goals are roughly in balance.&#8221;
The Fed reiterated a data-driven approach and highlighted the need to monitor economic implications for future policy decisions, refraining from committing to a predetermined path.
The next Federal Open Market Committee (FOMC) meeting is scheduled for December 18, 2024.
Financial markets are placing a 66% probability on another 25-basis-point cut at the year's final meeting, as per CME FedWatch, though expectations have dropped significantly following this week&#8217;s election results.
Market attention now shifts to Fed Chair Jerome Powell's press conference at 2:30 p.m. ET. 
Powell is expected to face questions on potential inflationary pressures from Trump&#8217;s trade tariffs and anticipated higher budget deficits and how the Fed might respond to changes in the <a href="https://www.benzinga.com/markets/equities/24/11/41785495/us-treasuries-take-sharpest-plunge-in-a-year-ahead-of-fed-meeting-could-powell-adjust-stance-in-">economic and political landscape</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41814589/why-trumps-boost-to-treasury-yields-inflation-expectations-may-weaken-feds-efforts-">Why Trump&#8217;s Boost To Treasury Yields, Inflation Expectations May Weaken Fed&#8217;s Efforts To Cut Interest Rates</a></li>
</ul>
Illustration of Federal Reserve Chair Jerome Powell created using artificial intelligence via MidJourney.

Macro Economic Events

Econ #s

Economics

Federal Reserve

Fed Cuts Interest Rates To Lowest Since February 2023, Sticks To Data-Driven Path

Craig-Hallum analyst Jeff Van Rhee maintains Fastly (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FSLY#NYSE">FSLY</a>) with a Hold and raises the price target from $6 to $8.

FSLY

Craig-Hallum Maintains Hold on Fastly, Raises Price Target to $8

DA Davidson analyst Tom White maintains Zillow Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZG#NASDAQ">ZG</a>) with a Buy and raises the price target from $71 to $75.

DA Davidson Maintains Buy on Zillow Gr, Raises Price Target to $75

WIIM

FBIN

Fortune Brands shares are trading lower after the company reported worse-than-expected Q3 revenue results and cut its FY24 guidance. Multiple firms lowered their respective price targets on the stock.

Bernstein analyst Stacy Rasgon maintains Qualcomm (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QCOM#NASDAQ">QCOM</a>) with a Outperform and raises the price target from $200 to $215.

QCOM

Bernstein Maintains Outperform on Qualcomm, Raises Price Target to $215

DA Davidson analyst Rudy Kessinger maintains Rapid7 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPD#NASDAQ">RPD</a>) with a Neutral and raises the price target from $35 to $39.

DA Davidson Maintains Neutral on Rapid7, Raises Price Target to $39

DBGI

Digital Brands Group Repays All Convertible Debt Securities, Extinguishing Obligations Under Securities Purchase Agreements; Announces Debt-Free Status In Press Release

Craig-Hallum analyst Greg Palm maintains Faro Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FARO#NASDAQ">FARO</a>) with a Buy and raises the price target from $25 to $30.

FARO

Craig-Hallum Maintains Buy on Faro Technologies, Raises Price Target to $30

Dutch Bros Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BROS#NYSE">BROS</a>) stock hit a new 52-week high on Thursday after the company reported better-than-expected financial results and raised its full-year guidance above estimates. Here&#8217;s what <a href="https://www.benzinga.com/news/earnings/24/11/41791482/dutch-bros-stock-perks-up-after-solid-q3-earnings-report-details">you need to know</a>. 
The Details: Dutch Bros stock soared about 15% after the market closed on Wednesday following the release of the company&#8217;s third-quarter earnings, which included adjusted earnings per share of 16 cents, beating analyst estimates of 12 cents.
In addition, the company reported sales of $338.21 million, beating analyst estimates of $325.14 million. Dutch Bros&#8217; top-line results were up about 28% year-over-year. The company also reported company-operated shop revenues of $308.3 million, representing a 30% year-over-year increase.
The company reported adjusted EBITDA of $63.8 million, compared to $53 million in the same period last year. Dutch Bros also reported adjusted selling, general and administrative expenses totaling $57.5 million.
Throughout the third quarter, Dutch Bros opened 38 new stores across 11 states with 33 of those stores being company-operated.
&#8220;We believe our refined real estate strategy is working, as we are seeing strong new shop productivity as we have shifted our development focus and elevated our site selection process,&#8221; said Dutch Bros CEO Christine Barone.
&#8220;We continue to demonstrate remarkable consistency in our shop opening cadence with 38 shop openings in the&nbsp;third quarter. We are making major investments in our development and construction teams and our 2025 pipeline is strong, positioning us to accelerate new shop growth.&#8221;
Dutch Bros also raised its guidance for the full year above estimates. The company now expects revenue between $1.25 billion and $1.26 billion, versus analyst estimates of $1.23 billion. Dutch Bros previously guided for revenue of $1.21 billion to $1.23 billion.
Additionally, Dutch Bros said it expects adjusted EBITDA of $215 million to $220 million, up from its prior outlook of $200 million to $210 million.
See Also:<a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41792455/jpmorgan-bank-of-america-and-wells-fargo-shares-surged-wednesday-heres-why"> JPMorgan, Bank Of America And Wells Fargo Shares Surged Wednesday: Here&#8217;s Why</a>
Analyst Changes: Following the earnings report, multiple analysts issued price target adjustments.
<ul>
<li>TD Cowen analyst Andrew Charles maintained a Buy rating on Dutch Bros and raised the price target from&nbsp;$47&nbsp;to&nbsp;$53.</li>
<li>Wedbush analyst Nick Setyan maintained an Outperform rating on Dutch Bros and raised the price target from $45 to $55.</li>
<li>UBS analyst Dennis Geiger maintained a Buy rating on Dutch Bros and raised the price target from&nbsp;$39&nbsp;to&nbsp;$44.</li>
<li>Baird analyst David Tarantino maintained a Neutral rating on Dutch Bros and raised the price target from $37 to $46.</li>
<li>JPMorgan analyst John Ivankoe maintained an Overweight rating and raised the price target from $44 to $48.</li>
</ul>
BROS Price Action: At the time of writing, Dutch Bros stock was up 32.7% at $46.38, according to data from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Image: Courtesy of Dutch Bros Inc.

Guidance

Movers

BROS

Dutch Bros Stock Hits 52-Week Highs: What's Going On?

Argus Research analyst John Staszak maintains Restaurant Brands Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QSR#NYSE">QSR</a>) with a Buy and lowers the price target from $85 to $80.

Argus Research Maintains Buy on Restaurant Brands Intl, Lowers Price Target to $80

DA Davidson analyst Rudy Kessinger maintains Fastly (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FSLY#NYSE">FSLY</a>) with a Neutral and raises the price target from $5.5 to $7.5.

DA Davidson Maintains Neutral on Fastly, Raises Price Target to $7.5

On Thursday, Emergent BioSolutions Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EBS#NYSE">EBS</a>) stock is trading higher on mixed third-quarter earnings and a new mpox trial in Africa.
The company reported third-quarter sales of $293.8 million, up 9% year over year, with the management guidance of $265&nbsp;million–$315 million, and missing the&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of $297.5 million</a>.
The company reported an adjusted EPS of $1.37, a turnaround from a loss of $1.09 a year ago,&nbsp;beating <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/g41786475/emergent-biosolutions-reports-third-quarter-2024-financial-results" rel="noreferrer noopener">the consensus of $0.14</a>.
Revenues from Narcan&nbsp;(naloxone HCl) Nasal Spray decreased 33% to $95.3 million, primarily driven by the discontinuation of prescription Narcan&nbsp;due to the launch of over-the-counter Narcan&nbsp;in the third quarter of 2023 and lower Canadian retail sales, partially offset by higher sales of OTC Narcan.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/41026819/emergent-biosolutions-confirms-orders-worth-400m-related-to-smallpox-mpox-vaccines" rel="noreferrer noopener">Emergent BioSolutions Confirms Orders Worth $400M Related To Smallpox, Mpox Vaccines</a>
Revenues from Anthrax MCM fell 65% to $11.4 million, and Smallpox MCM sales jumped more than fivefold to $132.7 million.
Guidance: Emergent BioSolutions updated its 2024 revenue guidance from $1.05 billion &#8211; $1.125 billion to $1.065 billion &#8211; $1.125 billion, compared to the consensus of $1.123 billion.
The updated guidance includes commercial product sales of $420&nbsp;million &#8211;&nbsp;$430 million compared to <a target="_blank" href="https://www.benzinga.com/general/biotech/24/08/40226161/vaccine-maker-emergent-biosolutions-expects-deeper-losses-in-2024-stock-sinks" rel="noreferrer noopener">prior guidance of </a>$450 million – $480 million.
MCM Product sales outlook of $510&nbsp;million &#8211; $550 million, compared to $455&nbsp;million – $490 million expected earlier.
Services segment sales are expected to be $105&nbsp;million &#8211; $110 million, lower than the prior range of $120&nbsp;million – $130 million.
The company expects a 2024 net loss of $203 million &#8211; $183 million, compared to the previous loss range of $314 million – $274 million, and an adjusted EBITDA of $180 million &#8211; $200 million compared to previous forecast of $140 million &#8211; $180 million.
Concurrently, Emergent BioSolutions announced that brincidofovir (brand name Tembexa for smallpox treatment) will be included in a trial conducted and sponsored by PANTHER, under the leadership of the Africa Centres for <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/g41789320/emergent-biosolutions-supports-new-clinical-trial-evaluating-the-safety-and-efficacy-of-brincidofo" rel="noreferrer noopener">Disease Control and Prevention</a>.
The study will evaluate the safety and efficacy of brincidofovir in treating mpox virus. The trial is scheduled to begin in the coming weeks in the Democratic Republic of Congo and neighboring countries.
Price Action: EBS stock is up 28.3% at $11.80 at last check Thursday.
Photo via Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/11/41816035/ralph-lauren-soars-as-q2-results-outpace-expectations-ceo-eyes-holiday-season-with-raised-revenue-g" target="_blank" rel="noreferrer noopener">Ralph Lauren Soars As Q2 Results Outpace Expectations—CEO Eyes Holiday Season With Raised Revenue Goals</a></li>
</ul>

Biotech

Earnings

Equities

Health Care

Trading Ideas

General

Mpox Vaccine Player Emergent BioSolutions Stock Jumps On Upbeat Annual Forecast, Expects Smaller Losses In 2024

DA Davidson analyst Kurt Yinger maintains TopBuild (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLD#NYSE">BLD</a>) with a Buy and lowers the price target from $460 to $450.

DA Davidson Maintains Buy on TopBuild, Lowers Price Target to $450

Argus Research analyst Joseph Bonner maintains Electronic Arts (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EA#NASDAQ">EA</a>) with a Buy and raises the price target from $161 to $183.

Argus Research Maintains Buy on Electronic Arts, Raises Price Target to $183

Craig-Hallum analyst Richard Shannon maintains IonQ (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IONQ#NYSE">IONQ</a>) with a Buy and raises the price target from $15 to $22.

IONQ

Craig-Hallum Maintains Buy on IonQ, Raises Price Target to $22

Moleculin Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBRX#NASDAQ">MBRX</a>) is set to give its latest quarterly earnings report on Friday, 2024-11-08. Here's what investors need to know before the announcement.
Analysts estimate that Moleculin Biotech will report an earnings per share (EPS) of $-2.44. 
Investors in Moleculin Biotech are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.
It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.
<h3>Overview of Past Earnings</h3>
In the previous earnings release, the company beat EPS by $0.61, leading to a 10.8% drop in the share price the following trading session.
Here's a look at Moleculin Biotech's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-2.31</td>
<td>-3.53</td>
<td>-3.05</td>
<td>-3.60</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-1.70</td>
<td>-2.02</td>
<td>-5.09</td>
<td>-2.85</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-11.0%</td>
<td>-0.0%</td>
<td>-14.000000000000002%</td>
<td>-5.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1731006266_0.png" alt="eps graph" />
<h3>Market Performance of Moleculin Biotech's Stock</h3>
Shares of Moleculin Biotech were trading at $2.36 as of November 06. Over the last 52-week period, shares are down 71.6%. Given that these returns are generally negative, long-term shareholders are likely upset going into this earnings release. 
<a href="https://www.benzinga.com/quote/MBRX/earnings">To track all earnings releases for Moleculin Biotech visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

MBRX

Insights Ahead: Moleculin Biotech's Quarterly Earnings

ANI Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANIP#NASDAQ">ANIP</a>) is preparing to release its quarterly earnings on Friday, 2024-11-08. Here's a brief overview of what investors should keep in mind before the announcement.
Analysts expect ANI Pharmaceuticals to report an earnings per share (EPS) of $1.07.
Anticipation surrounds ANI Pharmaceuticals's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.
New investors should understand that while earnings performance is important, market reactions are often driven by guidance.
<h3>Earnings History Snapshot</h3>
Last quarter the company beat EPS by $0.08, which was followed by a 9.92% drop in the share price the next day.
Here's a look at ANI Pharmaceuticals's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.94</td>
<td>0.99</td>
<td>0.85</td>
<td>0.84</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>1.02</td>
<td>1.21</td>
<td>1</td>
<td>1.27</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-10.0%</td>
<td>3.0%</td>
<td>-1.0%</td>
<td>-4.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1731006258_0.png" alt="eps graph" />
<h3>ANI Pharmaceuticals Share Price Analysis</h3>
Shares of ANI Pharmaceuticals were trading at $58.4 as of November 06. Over the last 52-week period, shares are up 12.64%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<h3>Analyst Observations about ANI Pharmaceuticals</h3>
For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on ANI Pharmaceuticals.
Analysts have given ANI Pharmaceuticals a total of 5 ratings, with the consensus rating being Neutral. The average one-year price target is $73.4, indicating a potential 25.68% upside.
<h3>Comparing Ratings Among Industry Peers</h3>
The following analysis focuses on the analyst ratings and average 1-year price targets of Tilray Brands, Collegium Pharmaceutical and Evolus, three prominent industry players, providing insights into their relative performance expectations and market positioning.
<ul>
<li>For Tilray Brands, analysts project an Neutral trajectory, with an average 1-year price target of $1.75, indicating a potential 97.0% downside.</li>
<li>The consensus outlook from analysts is an Buy trajectory for Collegium Pharmaceutical, with an average 1-year price target of $41.5, indicating a potential 28.94% downside.</li>
<li>The consensus outlook from analysts is an Buy trajectory for Evolus, with an average 1-year price target of $24.6, indicating a potential 57.88% downside.</li>
</ul>
<h3>Snapshot: Peer Analysis</h3>
Within the peer analysis summary, vital metrics for Tilray Brands, Collegium Pharmaceutical and Evolus are presented, shedding light on their respective standings within the industry and offering valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>ANI Pharmaceuticals</td>
<td>Neutral</td>
<td>18.44%</td>
<td>$80.34M</td>
<td>-0.59%</td>
</tr>
<tr>
<td>Tilray Brands</td>
<td>Neutral</td>
<td>13.05%</td>
<td>$59.71M</td>
<td>-1.13%</td>
</tr>
<tr>
<td>Collegium Pharmaceutical</td>
<td>Buy</td>
<td>7.18%</td>
<td>$90.81M</td>
<td>8.94%</td>
</tr>
<tr>
<td>Evolus</td>
<td>Buy</td>
<td>35.59%</td>
<td>$47.83M</td>
<td>-60.12%</td>
</tr>
</tbody>
</table>

Key Takeaway:
ANI Pharmaceuticals ranks in the middle for consensus rating among its peers. It is at the bottom for revenue growth. In terms of gross profit, it is at the top among its peers. However, for return on equity, it is at the bottom compared to its peers.
<h3>Discovering ANI Pharmaceuticals: A Closer Look</h3>
ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid dose products. Its areas of product development include narcotics, oncolytic, hormones and steroids, and complex formulations involving extended release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.
<h3>A Deep Dive into ANI Pharmaceuticals's Financials</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Revenue Growth: ANI Pharmaceuticals's remarkable performance in 3 months is evident. As of 30 June, 2024, the company achieved an impressive revenue growth rate of 18.44%. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of -1.95%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): ANI Pharmaceuticals's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of -0.59%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): ANI Pharmaceuticals's ROA excels beyond industry benchmarks, reaching -0.29%. This signifies efficient management of assets and strong financial health.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.63.
<a href="https://www.benzinga.com/quote/ANIP/earnings">To track all earnings releases for ANI Pharmaceuticals visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ANIP

A Peek at ANI Pharmaceuticals's Future Earnings

InflaRx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IFRX#NASDAQ">IFRX</a>) is gearing up to announce its quarterly earnings on Friday, 2024-11-08. Here's a quick overview of what investors should know before the release.
Analysts are estimating that InflaRx will report an earnings per share (EPS) of $-0.28.
InflaRx bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Earnings History Snapshot</h3>
Last quarter the company missed EPS by $0.05, which was followed by a 2.99% increase in the share price the next day.
Here's a look at InflaRx's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.21</td>
<td>-0.24</td>
<td>-0.2</td>
<td>-0.25</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.26</td>
<td>-0.18</td>
<td>-0.3</td>
<td>-0.14</td>
</tr>
<tr>
<td>Price Change %</td>
<td>3.0%</td>
<td>0.0%</td>
<td>-3.0%</td>
<td>-14.000000000000002%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1731006244_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of InflaRx were trading at $1.53 as of November 06. Over the last 52-week period, shares are up 17.97%. Given that these returns are generally positive, long-term shareholders should be satisfied going into this earnings release. 
<a href="https://www.benzinga.com/quote/IFRX/earnings">To track all earnings releases for InflaRx visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

IFRX

Earnings Preview: InflaRx

Craig-Hallum analyst Greg Palm maintains Kornit Digital (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRNT#NASDAQ">KRNT</a>) with a Buy and raises the price target from $27 to $33.

KRNT

Craig-Hallum Maintains Buy on Kornit Digital, Raises Price Target to $33

The gaming peripheral industry is evolving rapidly due to increasing internet penetration worldwide, in confluence with the introduction of gaming PCs and laptops. So, let's analyze Logitech International (LOGI) and Corsair Gaming (CRSR) to determine which gaming peripheral stock has the edge ahead of earnings. Read more... The global gaming peripherals market is driven by the growing number of gaming enthusiasts in conjunction with the rising popularity of e-sports tournaments. The industry is further aided by the popularity of e-sports and other games, which have led to the launch of specialized gaming keyboards and gamepads. 
The global gaming peripheral market is predicted to grow at a <a href="https://www.expertmarketresearch.com/reports/gaming-peripherals-market">CAGR of 10.3%</a> during 2024-2032.   
Moreover, based on the <a href="https://www.businessresearchinsights.com/market-reports/pc-gaming-peripheral-market-102969">rising need for a user-friendly interface</a>, availability of hardware in a small size, and rising popularity, gaming consoles are likely to see rapid growth in the near future. An increasing number of dedicated players worldwide is driving the need for an improved gaming experience.
Against this backdrop, let's compare two <a href="https://stocknews.com/category/technology-hardware/">Technology - Hardware</a> stocks, Logitech International S.A. (<a href="https://stocknews.com/stock/LOGI/">LOGI</a>) and Corsair Gaming, Inc. (<a href="https://stocknews.com/stock/CRSR/">CRSR</a>), to analyze which gaming peripheral stock has the edge ahead of their earnings.
The Case for Logitech International S.A. stock
Valued at $14.71 billion by market cap, Logitech International S.A. (<a href="https://stocknews.com/stock/LOGI/">LOGI</a>) designs, manufactures, and markets software-enabled hardware solutions that connect people to working, creating, gaming, and streaming worldwide. The company is based in Lausanne, Switzerland.
On August 19, 2024, LOGI announced that it has partnered with Aimlabs, a platform developed by State Space Labs, Inc., to introduce The Gauntlet. This exciting new competition was part of the Global Logitech G PLAYDAYS initiative and features over $100,000 in cash and prizes for participants.
LOGI's stock has gained 31.9% over the past year to close the last trading session at $89.12.
In terms of the trailing-12-month <a href="https://www.investopedia.com/terms/a/assetturnover.asp">asset turnover ratio</a>, LOGI's 1.24x is 99.4% higher than the 0.62x industry average. Likewise, its 15.18% trailing-12-month EBIT margin is 203.6% higher than the 5% industry average.
LOGI's net sales for the first quarter that ended June 30, 2024, came in at $1.09 billion, up 77.4% year-over-year. Its non-GAAP operating income rose 67% year-over-year to $182.44 million. Its non-GAAP net income increased 68.9% year-over-year to $174.63 million, and its non-GAAP net income per share grew 73.8% over the previous year's quarter to $1.13.
Street expects LOGI's revenue for the second quarter ending September 2024 to increase 5% year-over-year to $1.11 billion. Its EPS is expected to be $1.07 for the same quarter. Moreover, the company surpassed consensus revenue and EPS estimates in each of the trailing four quarters.
LOGI's strong fundamentals are reflected in its <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a>. The stock has an overall B rating, equating to Buy in our proprietary rating system. The POWR Ratings are calculated by considering 118 distinct factors, with each factor weighted to an optimal degree.
LOGI has an A grade for Quality. It is ranked #14 out of 41 stocks in the <a href="https://stocknews.com/category/technology-hardware/">Technology - Hardware</a> industry.
<a href="https://stocknews.com/stock/LOGI/">Click here</a> for the additional POWR Ratings for LOGI (Value, Growth, Sentiment, Stability, and Momentum).
The Case for Corsair Gaming, Inc. stock
Valued at $731.11 million by market cap, Corsair Gaming, Inc. (<a href="https://stocknews.com/stock/CRSR/">CRSR</a>) designs, develops, markets, and sells gaming and streaming peripherals, components, and systems in the Americas, Europe, the Middle East, and the Asia Pacific.
CRSR's stock has declined 39.7% over the past three months to close the last trading session at $7.02.
In terms of the trailing-12-month gross profit margin, CRSR's 24.78% is 50.3% lower than the 49.85% industry average. Likewise, its 1.95% trailing-12-month EBITDA margin is 80.4% lower than the industry average of 9.97%.
CRSR's net revenue for the second quarter that ended June 30, 2024, declined 80.3% year-over-year to $261.30 million. The company's net loss and net loss per share attributable to common stockholders of CRSR came in at $23.51 million and $0.28, up significantly from the prior year's quarter, respectively.
Street expects CRSR's revenue for the quarter ending September 2024 to decline 16.7% year-over-year to $302.44 million. The company's EPS for the same quarter is expected to decline 53% year-over-year to $0.06. Moreover, the company has failed to surpass consensus EPS estimates in each of the trailing four quarters.
CRSR's bleak fundamentals are reflected in its POWR Ratings. The stock has an overall D rating, translating to a Sell in our proprietary rating system.
The stock has a D grade for Stability, Sentiment, and Quality. Within the same industry, CRSR is ranked #34.
In addition to the POWR Ratings I've just highlighted, you can see CRSR's ratings for Growth, Momentum, and Value <a href="https://stocknews.com/stock/CRSR/">here</a>.
Corsair (CRSR) vs. Logitech (LOGI): Which Gaming Peripheral Stock Has the Edge Ahead of Earnings?
The exponential rise in the popularity of esports and competitive gaming majorly drives the global gaming peripheral market. Professional and amateur gamers seek equipment that offers precision, responsiveness, and customization options to gain a competitive edge. Furthermore, the ever-evolving gaming landscape fuels a constant need for innovation in peripherals. 
Both LOGI and CRSR stand to capitalize on these burgeoning industry trends. However, LOGI's higher profitability and strong analysts' sentiments favor it as the better gaming stock pick.
Our research shows that the odds of success increase when one invests in stocks with an Overall Rating of Strong Buy or Buy. View all the top-rated stocks in the Technology - Hardware industry <a href="https://stocknews.com/category/technology-hardware/">here</a>.
What To Do Next?
43 year investment veteran, Steve Reitmeister, has just released his 2024 market outlook along with trading plan and top 11 picks for the year ahead.
<a href="https://report.stocknews.com/sign-up/stock-market-outlook-2024/?formplacement=artbotad_smo24_rep">2024 Stock Market Outlook &gt;</a>

<hr />
LOGI shares were trading at $89.19 per share on Monday afternoon, up $0.10 (+0.11%). Year-to-date, LOGI has declined -6.18%, versus a 21.13% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: Nidhi Agarwal</h2> <img src='https:/wp-content/uploads/2023/03/Nidhi-Agarwal_Headshot-3.jpg' style="float:left; padding:5px;width:125px;">Nidhi is passionate about the capital market and wealth management, which led her to pursue a career as an investment analyst. She holds a bachelor's degree in finance and marketing and is pursuing the CFA program.

Her fundamental approach to analyzing stocks helps investors identify the best investment opportunities.<a href="https://stocknews.com/authors/?author=nidhi-agarwal">More...</a>The post <a href=https://stocknews.com/news/logi-crsr-corsair-crsr-vs-logitech-logi-which-gaming-peripheral-stock-has/>Corsair (CRSR) vs. Logitech (LOGI): Which Gaming Peripheral Stock Has the Edge Ahead of Earnings?</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

Corsair (CRSR) vs. Logitech (LOGI): Which Gaming Peripheral Stock Has the Edge Ahead of Earnings?

Logitech: Growth Tailwinds With Upside In Valuation

Corsair Gaming: May Be Worth A Second Look, A 'Buy' From Me

September videogame sales down 6% in the U.S., led by sharp drop in console spends

Corsair Gaming Non-GAAP EPS of -$0.29 misses by $0.35, revenue of $304.2M beats by $1.69M

Corsair Gaming, Inc. (CRSR) Q3 2024 Earnings Call Transcript

Corsair Gaming, Inc. ( ($CRSR) ) has released its Q3 earnings. Here is a breakdown of the information Corsair Gaming, Inc. presented to its investo...

Corsair Gaming Announces Q3 2024 Financial Results

Barclays analyst George Wang CFA maintained a Buy rating on Corsair Gaming (CRSR – Research Report) today and set a price target of $9.00. The comp...

Corsair Gaming (CRSR) Receives a Buy from Barclays

Barclays lowered the firm's price target on Corsair Gaming (CRSR) to $9 from $14 and keeps an Overweight rating on the shares. The firm says lower ...

Corsair Gaming price target lowered to $9 from $14 at Barclays

Freshworks, IonQ among tech stocks soaring after earnings, while Dynatrace dips

APPN

CCOEF

CCOEY

CRSR

ESPO

FRSH

GAMR

HEAR

KNAMF

KONMY

LOGI

MSFT

NCBDF

NCBDY

NERD

NEXOF

NEXOY

NTDOF

NTDOY

NTES

RBLX

SGAMF

SGAMY

SKLZ

SONY

SQNNY

SQNXF

TCEHY

TCTZF

TTWO

UBSFF

UBSFY

Press Releases

Corsair Gaming to Report Q2 2024 Financial Results on August 1; Provides Preliminary Q2 2024 Results

Corsair Gaming Reports Q2 2024 Financial Results

Elgato Launches Stream Deck Studio; Collaboration with Bitfocus Brings Highly Popular Stream Deck to Professional Broadcasters

Corsair Set to Acquire the Fanatec Product Line from Endor AG

CORSAIR Announces Exclusive Multi-Year, Cross Brand Partnership with Call of Duty® Franchise

Corsair Closed Acquisition of the Fanatec Product Line from Endor AG; Moves into Sim Racing's Pole Position

CORSAIR Launches High-Performance Products in Multi-Year, Cross Brand Collaboration with Call of Duty®

CORSAIR Launches VIRTUOSO MAX Headset with Active Noise Cancellation and Dolby Atmos for Ultra-Immersive Gaming; Available in Both PC and Xbox Versions

Comments

Corsair Gaming

Corsair Gaming (CRSR) Opciones

Corsair Gaming (NASDAQ:CRSR) Bolsa, Cadena de Opciones

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL